{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:49:41Z","timestamp":1761630581920},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.2515\/therapie\/2011015","type":"journal-article","created":{"date-parts":[[2011,6,3]],"date-time":"2011-06-03T15:11:49Z","timestamp":1307113909000},"page":"103-108","source":"Crossref","is-referenced-by-count":3,"title":["Niveau de preuve du suivi th\u00e9rapeutique pharmacologique de l\u2019itraconazole"],"prefix":"10.1016","volume":"66","author":[{"given":"Marie","family":"Charles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantal","family":"Le Guellec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Richard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Libert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.2515\/therapie\/2011015_bb0005","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1200\/JCO.2003.04.052","article-title":"Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients","volume":"21","author":"Glasmacher","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.2515\/therapie\/2011015_bb0010","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/jac\/dki440","article-title":"An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia","volume":"57","author":"Glasmacher","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.2515\/therapie\/2011015_bb0015","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0002-9343(94)90023-X","article-title":"NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis","volume":"97","author":"Denning","year":"1994","journal-title":"Am J Med"},{"key":"10.2515\/therapie\/2011015_bb0020","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000069281","article-title":"Intravenous itraconazole followed by oral itraconazole for the treatment of amphotericin-B-refractory invasive pulmonary aspergillosis","volume":"109","author":"Caillot","year":"2003","journal-title":"Acta Haematol"},{"issue":"Suppl 3","key":"10.2515\/therapie\/2011015_bb0025","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1086\/376526","article-title":"Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review","volume":"37","author":"Denning","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.2515\/therapie\/2011015_bb0030","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1365-2141.2005.05727.x","article-title":"Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials","volume":"131","author":"Vardakas","year":"2005","journal-title":"Br J Haematol"},{"key":"10.2515\/therapie\/2011015_bb0035","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1001\/archinte.1989.00390100107024","article-title":"Itraconazole therapy for cryptococcal meningitis and cryptococcosis","volume":"149","author":"Denning","year":"1989","journal-title":"Arch Intern Med"},{"key":"10.2515\/therapie\/2011015_bb0040","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1128\/AAC.35.4.707","article-title":"High-dose itraconazole in the treatment of severe mycoses","volume":"35","author":"Sharkey","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"issue":"4\/5","key":"10.2515\/therapie\/2011015_bb0045","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/0959-8049(92)90127-N","article-title":"Plasma itraconazole concentrations in neutropenic patients after repeated high-dose treatment","volume":"28A","author":"Persat","year":"1992","journal-title":"Eur J Cancer"},{"key":"10.2515\/therapie\/2011015_bb0050","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s002280050280","article-title":"Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole","volume":"52","author":"Jaruratanasirikul","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"10.2515\/therapie\/2011015_bb0055","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1128\/AAC.32.9.1310","article-title":"Pharmacokinetics of itraconazole following oral administration to normal volunteers","volume":"32","author":"Hardin","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie\/2011015_bb0060","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/BF00558308","article-title":"The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects","volume":"36","author":"Van Peer","year":"1989","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"10.2515\/therapie\/2011015_bb0065","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1128\/AAC.42.7.1862","article-title":"Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers","volume":"42","author":"Barone","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 1","key":"10.2515\/therapie\/2011015_bb0070","doi-asserted-by":"crossref","first-page":"i17","DOI":"10.1093\/jac\/dki220","article-title":"Making sense of itraconazole pharmacokinetics","volume":"56","author":"Prentice","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.2515\/therapie\/2011015_bb0075","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.2042-7158.1992.tb05478.x","article-title":"The pharmacokinetics of oral itraconazole in AIDS patients","volume":"44","author":"Smith","year":"1992","journal-title":"J Pharm Pharmacol"},{"issue":"suppl 1","key":"10.2515\/therapie\/2011015_bb0080","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1439-0507.1989.tb02296.x","article-title":"The clinical pharmacokinetics of itraconazole: an overview","volume":"32","author":"Heykants","year":"1989","journal-title":"Mycoses"},{"key":"10.2515\/therapie\/2011015_bb0085","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1365-2710.2001.00338.x","article-title":"Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics","volume":"26","author":"Willems","year":"2001","journal-title":"J Clin Pharm Ther"},{"key":"10.2515\/therapie\/2011015_bb0090","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S1043-6618(02)00088-9","article-title":"Itraconazole solution: summary of pharmacokinetic features and review of activity in the treatment of fluconazoleresistant oral candidosis in HIV-infected persons","volume":"46","author":"Koks","year":"2002","journal-title":"Pharmacol Res"},{"key":"10.2515\/therapie\/2011015_bb0095","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2165\/00003495-198937030-00003","article-title":"Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses","volume":"37","author":"Grant","year":"1989","journal-title":"Drugs"},{"key":"10.2515\/therapie\/2011015_bb0100","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1128\/AAC.32.10.1595","article-title":"Itraconazole pharmacokinetics in patients with renal dysfunction","volume":"32","author":"Boelaert","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie\/2011015_bb0105","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10096-005-1281-2","article-title":"Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis","volume":"24","author":"Girois","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"10.2515\/therapie\/2011015_bb0110","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/AAC.46.1.160-165.2002","article-title":"Interaction of common azole antifungals with P glycoprotein","volume":"46","author":"Wang","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.2515\/therapie\/2011015_bb0115","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jchromb.2009.11.017","article-title":"Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC\/MS\/MS","volume":"878","author":"Alffenaar","year":"2010","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"10","key":"10.2515\/therapie\/2011015_bb0120","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1128\/AAC.37.10.2224","article-title":"Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations","volume":"37","author":"Hostetler","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie\/2011015_bb0125","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1128\/AAC.38.6.1303","article-title":"Itraconazole in experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole plasma concentrations","volume":"38","author":"Berenguer","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie\/2011015_bb0130","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1136\/jcp.50.6.477","article-title":"Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis","volume":"50","author":"Cartledge","year":"1997","journal-title":"J Clin Pathol"},{"key":"10.2515\/therapie\/2011015_bb0135","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJM199103073241003","article-title":"Pulmonary aspergillosis in the acquired immunodeficiency syndrome","volume":"324","author":"Denning","year":"1991","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.2515\/therapie\/2011015_bb0140","first-page":"S94","article-title":"Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies","volume":"9","author":"Tricot","year":"1987","journal-title":"Rev Infect Dis"},{"issue":"Suppl 1","key":"10.2515\/therapie\/2011015_bb0145","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1439-0507.1989.tb02299.x","article-title":"Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels","volume":"32","author":"Boogaerts","year":"1989","journal-title":"Mycoses"},{"key":"10.2515\/therapie\/2011015_bb0150","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1086\/605499","article-title":"Toxicodynamics of itraconazole: implications for therapeutic drug monitoring","volume":"49","author":"Lestner","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.2515\/therapie\/2011015_bb0155","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/QCO.0b013e3283184611","article-title":"Therapeutic drug monitoring for triazoles","volume":"21","author":"Hope","year":"2008","journal-title":"Curr Opin Infect Dis"},{"key":"10.2515\/therapie\/2011015_bb0160","first-page":"163","article-title":"Marked intra- and inter patient variability of itraconazole steady state plasma concentrations","volume":"51","author":"Poirier","year":"1996","journal-title":"Therapie"},{"issue":"10","key":"10.2515\/therapie\/2011015_bb0165","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1128\/AAC.32.10.1595","article-title":"Itraconazole pharmacokinetics in patients with renal dysfunction","volume":"32","author":"Boelaert","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 7","key":"10.2515\/therapie\/2011015_bb0170","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1469-0691.2006.01611.x","article-title":"Therapeutic drug monitoring of itraconazole and the relevance of pharmacokinetic interactions","volume":"12","author":"Dominguez-Gil Hurle","year":"2006","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.2515\/therapie\/2011015_bb0175","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/(SICI)1099-1069(1998030)16:1<33::AID-HON620>3.0.CO;2-9","article-title":"Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole","volume":"16","author":"Kanda","year":"1998","journal-title":"Hematol Oncol"},{"issue":"14","key":"10.2515\/therapie\/2011015_bb0180","first-page":"1885","article-title":"Therapeutic monitoring is necessary for the association itraconazole and efavirenz in a patient with AIDS and disseminated histoplasmosis AIDS","volume":"22","author":"Huet","year":"2008"},{"issue":"6","key":"10.2515\/therapie\/2011015_bb0185","first-page":"29","article-title":"M\u00e9thodologie pour l\u2019\u00e9valuation du niveau de preuve du suivi th\u00e9rapeutique pharmacologique","volume":"23","author":"Le Guellec","year":"2009","journal-title":"La Lettre du Pharmacologue"},{"issue":"6","key":"10.2515\/therapie\/2011015_bb0190","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2165\/00003088-199835060-00004","article-title":"Optimisation of itraconazole therapy using target drug concentrations","volume":"35","author":"Poirier","year":"1998","journal-title":"Clin Pharmacokinet"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716307508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716307508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T07:43:21Z","timestamp":1554277401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716307508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0040595716307508"],"URL":"https:\/\/doi.org\/10.2515\/therapie\/2011015","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}